Oral products company Blis Technologies upped its interim loss to $550,000 on higher marketing and patent costs, but expected to break even by the end of the year.
Sales for the six months ended September rose by a quarter, and total revenue rose by 18 per cent as Blis sought expansion overseas.
The company is not paying a dividend, and would not pay any tax.
Blis posted a loss of $391,000 a year earlier, but slightly increased its shareholder funds to $586,000.
The company posted a loss of $964,000 last year.
Blis was seeking a cornerstone shareholder, preferably involved in the same industry, and wanted to develop commercial relationships with global oral care companies.
The company already has two licensing and R&D agreements with Nestle Nutrition worth about $1 million, not expected to generate revenue for three years.
It is negotiating a marketing agreement with Dutch company DSM Nutriceuticals, with plans for a later research contract to expand into other products.
Shares in Blis were steady at 7.6c, having traded between 4.8c and 11.9c in the last year.